Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Conjunctivitis Conjunctival Diseases Conjunctivitis Conjunctivitis, Allergic Eye Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases

Age range

10 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model

Exclusion criteria

Under 10 years of age

Treatment and study plan

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Drug

Olopatadine Hydrochloride Ophthalmic Solution Vehicle

Drug

Inactive ingredients used as a placebo comparator

Primary outcomes

Daily ocular itching and redness scores

Time frame: Up to Day 14

Secondary outcomes

Percentage of patients with daily ocular itching and redness scores of 0

Time frame: Up to Day 14

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Important dates

Study start: 2006
Primary completion: 2006
Study completion: 2006
First posted: May 31, 2006
Registry last updated: Aug 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed